Clinical trials: Botulinum Toxin
Wrinkle
BTL-785F Device for Non-invasive Facial Rejuvenation in Patients Injected With Botulinum Toxin
This study will evaluate the clinical safety and the efficacy of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive facial treatment in patients injected with botulinum toxin.
- Trial name
- NCT05524766
- Testing
- BTL-785-7 Treatment
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Arm Spasticity
Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice
The aim of the study was to compare Dysport treatment results (as assessed by Modified Ashworth Scale (MAS) in the elbow joint 4 weeks post treatment) following two treatment techniques: the current clinical practice injection…
- Trial name
- NMJ (NCT01682148)
- Testing
- Botulinum toxin type A
- Where
- 23 sites in Denmark, Finland and 2 more
- Volunteers
- 100 people
- Sponsor
- Ipsen
Post-stroke Arm Spasticity
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)
Botulinum toxin A (BoNT-A) is effective and safe in alleviating post-stroke spasticity and reducing the burden of associated symptoms.
- Trial name
- EARLYBIRD (NCT01840475)
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Ipsen
Glabellar Lines
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines
- Trial name
- NCT06246552
- Testing
- JTM201
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Jetema USA Inc.
Moderate to Severe Glabellar Lines
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines.
- Trial name
- NCT06583486
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 488 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT_BTA_P3_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after…
- Trial name
- NCT06124794
- Testing
- PROTOXIN
- Where
- 3 sites in South Korea
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Migraine Disorders
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study…
- Trial name
- NCT03193359
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Glabellar Frown Lines
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).
- Trial name
- Head2Head (NCT00777803)
- Testing
- NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), OnabotulinumtoxinA (Vistabel®)
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 381 people
- Sponsor
- Merz Pharmaceuticals GmbH
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968942
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Glabellar Rhytides
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03a (NCT00752297)
- Testing
- Preservative-free Saline, Mentor Purified Toxin
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Mentor Worldwide, LLC
Torticollis
Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia
The purpose of this study is to evaluate swallowing efficiency in patients with cervical dystonia following treatment with botulinum toxin Type A.
- Trial name
- NCT01384214
- Testing
- botulinum toxin Type A
- Where
- Croatia
- Volunteers
- 28 people
- Sponsor
- Allergan
Knee Osteoarthritis
Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee
The purpose of the study is to evaluate the safety and tolerability of the drug product at each dose level.
- Trial name
- NCT02139319
- Testing
- Botulinum toxin
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Galderma R&D
Spasticity
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
The aim of the study is to describe the long term use of Botulinum Neurotoxin Type A (BoNT-A) in adult subjects affected with upper and/or lower limb spasticity who received treatment with BoNT-A for a minimum of three injections…
- Trial name
- RESULT (NCT04340336)
- Where
- 3 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Ipsen
Cerebral Palsy, Spastic Paraplegia and Hemiparesis
Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy
1. To assess the clinical and neurophysiological efficacy of Xeomin® vs. Botox® in children with spastic equine and equinovarus foot deformation in pediatric cerebral palsy 2.
- Conditions
- Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation
- Trial name
- XEBEC (NCT02188277)
- Testing
- Xeomin, Botox®
- Where
- 3 sites in Russia
- Volunteers
- 64 people
- Sponsor
- Merz Pharmaceuticals GmbH
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan